within Pharmacolibrary.Drugs.ATC.J;

model J05AR16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.00036666666666666667,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lamivudine and raltegravir is a fixed-dose combination antiretroviral medication used for the treatment of Human Immunodeficiency Virus (HIV) infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while raltegravir is an integrase inhibitor. This combination is currently approved and used for HIV treatment as part of antiretroviral therapy.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult subjects, as no direct clinical PK studies for the fixed-dose combination have been published. Estimates are based on separate published parameters for each drug, assuming standard oral dosing in adults without renal or hepatic impairment.</p><h4>References</h4><ol><li><p>Moreira, FL, et al., &amp; Lanchote, VL (2023). P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV. <i>Journal of clinical pharmacology</i> 63(2) 219–227. DOI:<a href=\"https://doi.org/10.1002/jcph.2152\">10.1002/jcph.2152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36087110/\">https://pubmed.ncbi.nlm.nih.gov/36087110</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR16;
